hydroquinone has been researched along with Hypermelanosis in 90 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the use of a nonablative, fractional, 1,927-nm diode laser with and without topical 2% hydroquinone (HQ) cream for moderate-to-severe facial hyperpigmentation in Fitzpatrick skin Types III-V." | 9.27 | The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types. ( Bolton, J; Fabi, SG; Jones, IT; Larsen, L; Vanaman Wilson, MJ, 2018) |
| " Hydroquinone (HQ) is the gold standard and remains the only prescription product available in the United States for the treatment of generalized facial hyperpigmentation." | 9.17 | Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. ( Banga, A; Jain, P; Makino, ET; Mehta, RC; Sigler, ML; Sonti, S, 2013) |
| "This investigator-blinded, randomized trial was conducted to compare a new hydroquinone (HQ)-free hyperpigmentation regimen against a leading HQ-based hyperpigmentation regimen for the treatment of facial hyperpigmentation and photoaging." | 9.17 | Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging. ( Fabi, SG; Goldman, MP, 2013) |
| "This pilot study demonstrates that serial glycolic acid peels provide an additional benefit, with minimal adverse effects, for the treatment of postinflammatory hyperpigmentation in dark-complexioned individuals." | 9.08 | Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. ( Burns, RL; Faria, DT; Fivenson, DP; Lawry, MA; Lawry, TB; Prevost-Blank, PL, 1997) |
| "LYT2 represents a new efficacious alternative to hydroquinone-based treatments for pregnancy-induced melasma." | 8.12 | Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum. ( Jiang, LI; Makino, ET; Mehta, RC; Mikati, M; Stephens, TJ, 2022) |
| "A 42-year-old woman being treated with 5-fluorouracil for carcinoma of the sigmoid colon developed persistent serpentine supravenous hyperpigmented eruption (PSSHE), bilateral mottling of the palms and diffuse hyperpigmentation of the soles." | 7.80 | 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. ( Agrawal, A; Parihar, A; Suvirya, S, 2014) |
| "The new treatment protocol combining Q-switched ruby laser and topical bleaching treatment using tretinoin and hydroquinone is considered effective for improvement of periorbital skin hyperpigmentation, with a low incidence of postinflammatory hyperpigmentation." | 7.74 | Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. ( Ban, I; Harii, K; Kobayashi, Y; Kurita, M; Miyamoto, S; Momosawa, A; Ozaki, M, 2008) |
| "Hydroquinone is a commonly used depigmenting agent in clinical practice for treating hyperpigmentation." | 6.82 | Hyperpigmentation: Looking beyond hydroquinone. ( Charoo, NA, 2022) |
| " rotundus essential oil (CREO) in treating axillary hyperpigmentation, and compare with another active treatment hydroquinone (HQ) and a placebo (cold cream) in this study." | 5.51 | Topical Cyperus rotundus essential oil for treatment of axillary hyperpigmentation: a randomized, double-blind, active- and placebo-controlled study. ( Mohammed, GF, 2022) |
| " The principal adverse effects of its chronic use are confetti-like depigmentation and exogenous ochronosis." | 5.35 | Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. ( Azulay-Abulafia, L; Barcaui, CB; Charlín, R; Kac, BK; Rabello-Fonseca, R; Soares, DB, 2008) |
| "To evaluate the use of a nonablative, fractional, 1,927-nm diode laser with and without topical 2% hydroquinone (HQ) cream for moderate-to-severe facial hyperpigmentation in Fitzpatrick skin Types III-V." | 5.27 | The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types. ( Bolton, J; Fabi, SG; Jones, IT; Larsen, L; Vanaman Wilson, MJ, 2018) |
| " Purpose: Though hydroquinone (HQ) remains the gold standard for treatment of hyperpigmentation, concerns about its safety have prompted the development of HQ-free topical skin lightening systems." | 5.24 | A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation. ( Bolton, J; Goldman, MP; Jones, IT; Larsen, L; Vanaman Wilson, MJ; Wu, DC, 2017) |
| "This double-blind, randomized, split-face study compares the effects of a new OTC non-hydroquinone lightening product (JM) to an available 4% hydroquinone lightening solution (OB) on the appearance of hyperpigmentation, texture, and ne lines and wrinkles." | 5.22 | Split-Face Comparison of an Advanced Non-Hydroquinone Lightening Solution to 4% Hydroquinone. ( Mohr, S; Saxena, S; Schlessinger, J, 2016) |
| " Hydroquinone (HQ) is the gold standard and remains the only prescription product available in the United States for the treatment of generalized facial hyperpigmentation." | 5.17 | Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. ( Banga, A; Jain, P; Makino, ET; Mehta, RC; Sigler, ML; Sonti, S, 2013) |
| "This investigator-blinded, randomized trial was conducted to compare a new hydroquinone (HQ)-free hyperpigmentation regimen against a leading HQ-based hyperpigmentation regimen for the treatment of facial hyperpigmentation and photoaging." | 5.17 | Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging. ( Fabi, SG; Goldman, MP, 2013) |
| "Compared with standard skin care, the HQ system plus tretinoin resulted in significantly milder fine lines/wrinkles and hyperpigmentation at Days 30, 90, and 120 (p ≤ ." | 5.15 | Further enhancement of facial appearance with a hydroquinone skin care system plus tretinoin in patients previously treated with botulinum toxin Type A. ( Kenkel, J; Schlessinger, J; Werschler, P, 2011) |
| "Long-term treatment with a high-strength hydroquinone (HQ) cream (usually 4% HQ) is the mainstay therapy for hyperpigmentation disorders." | 5.12 | A hydroquinone formulation with increased stability and decreased potential for irritation. ( Canning, MT; Dong, KK; Grimson, R; Smiles, KA; Walfield, AM; Yarosh, DB, 2007) |
| "Patients with facial mottled hyperpigmentation of at least moderate severity and an overall integrated assessment of photodamage score of at least moderate applied tazarotene 0." | 5.12 | Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study. ( Draelos, Z; Horwitz, S; Lowe, N; Menter, A; Tanghetti, E, 2006) |
| "Combination therapy of hydroquinone and retinol may improve photoaging-associated hyperpigmentation." | 5.11 | Novel approach to the treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream. ( Draelos, ZD, 2005) |
| "Hydroquinone is superior to tretinoin as a priming agent in maintaining the results achieved with peels and in decreasing the incidence of postpeel reactive hyperpigmentation." | 5.11 | Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. ( Grover, C; Nanda, S; Reddy, BS, 2004) |
| "To evaluate the efficiency and adverse effects of 10% all-trans retinol (ROL) gel for improvement of skin hyperpigmentation." | 5.10 | Clinical trial of bleaching treatment with 10% all-trans retinol gel. ( Aiba, E; Aoyama, T; Harii, K; Iga, T; Matsumoto, D; Mitoma, Y; Momosawa, A; Sato, K; Yoshimura, K, 2003) |
| " When instituted as a component of the skin care regimen postoperatively, topical hydroquinone, tretinoin and/or glycolic acid preparations may be helpful in reducing post-laser resurfacing hyperpigmentation." | 5.09 | Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. ( Alster, TS; West, TB, 1999) |
| "This pilot study demonstrates that serial glycolic acid peels provide an additional benefit, with minimal adverse effects, for the treatment of postinflammatory hyperpigmentation in dark-complexioned individuals." | 5.08 | Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. ( Burns, RL; Faria, DT; Fivenson, DP; Lawry, MA; Lawry, TB; Prevost-Blank, PL, 1997) |
| " Hydroquinone has been a cornerstone for the treatment of hyperpigmentation; however, concerns regarding adverse effects have prompted a search for alternative agents." | 4.88 | New horizons in treating disorders of hyperpigmentation in skin of color. ( Geria, AN; Halder, RM; Konda, S, 2012) |
| "LYT2 represents a new efficacious alternative to hydroquinone-based treatments for pregnancy-induced melasma." | 4.12 | Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum. ( Jiang, LI; Makino, ET; Mehta, RC; Mikati, M; Stephens, TJ, 2022) |
| " In this study we provide conclusive evidence of the inhibition mechanism of two well studied tyrosinase inhibitors, KA (kojic acid) and HQ (hydroquinone), which are extensively used in hyperpigmentation treatment." | 3.83 | The unravelling of the complex pattern of tyrosinase inhibition. ( Adir, N; Deri, B; Fishman, A; Goldfeder, M; Guallar, V; Kanteev, M; Lecina, D, 2016) |
| "A 42-year-old woman being treated with 5-fluorouracil for carcinoma of the sigmoid colon developed persistent serpentine supravenous hyperpigmented eruption (PSSHE), bilateral mottling of the palms and diffuse hyperpigmentation of the soles." | 3.80 | 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. ( Agrawal, A; Parihar, A; Suvirya, S, 2014) |
| "Exogenous ochronosis (EO), a disfiguring cutaneous complication of topical hydroquinone use, is difficult to treat." | 3.79 | Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser. ( Tan, SK, 2013) |
| "We describe a 63-year-old Hispanic woman who developed exogenous ochronosis lesions on her face after using topical bleaching creams containing hydroquinone, 2% to 3%, and oxybenzone, 2%, for several years." | 3.76 | Dermoscopic and reflectance confocal microscopic features of exogenous ochronosis. ( Gil, I; Herrero-González, JE; Lloreta, J; Martínez-Escala, E; Puig, S; Pujol, RM; Segura, S; Vélez, M, 2010) |
| "The new treatment protocol combining Q-switched ruby laser and topical bleaching treatment using tretinoin and hydroquinone is considered effective for improvement of periorbital skin hyperpigmentation, with a low incidence of postinflammatory hyperpigmentation." | 3.74 | Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. ( Ban, I; Harii, K; Kobayashi, Y; Kurita, M; Miyamoto, S; Momosawa, A; Ozaki, M, 2008) |
| "Exogenous ochronosis is a paradoxical hyper-pigmentation of the skin caused by the long-term use of hydroquinone-containing bleaching creams." | 3.73 | Exogenous ochronosis and striae atrophicae following the use of bleaching creams. ( Aricò, M; Bongiorno, MR, 2005) |
| "Hydroquinone has been successfully used to treat hyperpigmentation disorders for many years." | 3.72 | Lustra, Lustra-AF and Alustra. ( Gupta, AK; Ryder, JE, 2003) |
| "To report the effectiveness of a quality-switched (QS) 755-nm alexandrite laser in treating hydroquinone-induced exogenous ochronosis." | 3.72 | Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. ( Alster, TS; Bellew, SG, 2004) |
| " The treatment was repeated after a 1-month interval of tretinoin application in 4 patients: 2 desired further improvement in color, and 2 had the second course conducted to treat the postinflammatory hyperpigmentation on the surrounding mound induced by the first course." | 3.71 | Cosmetic color improvement of the nipple-areola complex by optimal use of tretinoin and hydroquinone. ( Aiba, E; Aoyama, T; Harii, K; Iga, T; Matsumoto, D; Momosawa, A; Sato, K; Watanabe, A; Yamamoto, T; Yoshimura, K, 2002) |
| "A novel topical product with PATH-3 Technology, designed to counteract various steps in pigmentation pathways, has been demonstrated to be safe and effective in treating facial dyschromia." | 3.30 | A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. ( Bajaj, S; Bell, M; Fabi, S; Geronemus, R; Robinson, D; Wang, J; Widgerow, A, 2023) |
| "Hyperpigmentation is a broad term to describe increased pigmentation in the skin, and making a correct diagnosis is an important first step in the successful management of hyperpigmentary disorders." | 2.82 | Differential diagnosis and management of hyperpigmentation. ( Yoo, J, 2022) |
| "Hydroquinone is a commonly used depigmenting agent in clinical practice for treating hyperpigmentation." | 2.82 | Hyperpigmentation: Looking beyond hydroquinone. ( Charoo, NA, 2022) |
| "The first-line treatment for hyperpigmentation involves topical formulations of conventional agents such as hydroquinone, kojic acid, and glycolic acid followed by oral formulations of therapeutic agents such as tranexamic acid, melatonin, and cysteamine hydrochloride." | 2.72 | Management of hyperpigmentation: Current treatments and emerging therapies. ( Nautiyal, A; Wairkar, S, 2021) |
| "Hydroquinone has pharmacological uses in disorders of pigmentation because of its ability to competitively inhibit the enzyme tyrosinase." | 2.72 | Hydroquinone: myths and reality. ( Al-Niaimi, F; Ali, FR; Searle, T, 2021) |
| "Hydroquinone 4% cream with 2% glycolic acid is safe and effective in improving photodamage on the neck and upper chest when used alone or in combination with salicylic acid peels." | 2.69 | Efficacy of hydroquinone cream (USP 4%) used alone or in combination with salicylic acid peels in improving photodamage on the neck and upper chest. ( Gladstone, HB; Jeffers, M; Moy, RL; Nguyen, SL; Ottomeyer, T; Williams, R; Wortzman, M, 2000) |
| "With proper treatment, melasma can be controlled, improved, and maintained; alternatively, PIH can be cured in most cases." | 2.53 | Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion. ( Emer, J; Prado, G; Sofen, B, 2016) |
| "Hyperpigmentation has traditionally been a relatively difficult condition to treat, especially in darker racial ethnic groups." | 2.48 | [Topical treatment of hyperpigmentation disorders]. ( Horwitz, S; Rendon, M, 2012) |
| "Hyperpigmentation has traditionally been a relatively difficult condition to treat, especially in darker racial ethnic groups." | 2.48 | Topical treatment of hyperpigmentation disorders. ( Horwitz, S; Rendon, M, 2012) |
| "Lymphomatoid papulosis is often regarded as a low-grade variant of cutaneous T cell lymphoma (CTCL)." | 1.48 | Lymphomatoid papulosis. ( Beasley, JM; Cohen, JM; Latkowski, JM; Meehan, SA; Wiznia, LE, 2018) |
| "Hydroquinone was bound to cellulose nanocrystals representing 79." | 1.42 | The Use of Cellulose Nanocrystals for Potential Application in Topical Delivery of Hydroquinone. ( Mohammadi, M; Taheri, A, 2015) |
| "Hyperpigmentation has frustrated men and women as a cosmetic concern and as a reminder of past skin injury." | 1.35 | Hyperpigmentation: old problem, new therapies. ( Bergstrom, KG; Que, SK, 2009) |
| " The principal adverse effects of its chronic use are confetti-like depigmentation and exogenous ochronosis." | 1.35 | Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. ( Azulay-Abulafia, L; Barcaui, CB; Charlín, R; Kac, BK; Rabello-Fonseca, R; Soares, DB, 2008) |
| "Hyperpigmentation is the most common cosmetic skin complaint in Asians, but there is no standard treatment strategy." | 1.35 | A therapeutic strategy based on histological assessment of hyperpigmented skin lesions in Asians. ( Kato, H; Kurita, M; Yoshimura, K, 2009) |
| "Hyperpigmentation was observed in 38." | 1.33 | Analysis of hyperpigmentation and hypopigmentation after Er:YAG laser skin resurfacing. ( Kim, SN; Kim, YJ; Kye, YC; Lee, HS; Son, SW, 2005) |
| "Acne was the most frequent motive for consulting (24%), followed by the paradoxical peri-orbital hyperpigmentation (21." | 1.33 | [Reasons for consulting related to skin-bleaching products used by 104 women in Brazzaville]. ( Gathse, A; Ibara, JR, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.33) | 18.7374 |
| 1990's | 5 (5.56) | 18.2507 |
| 2000's | 35 (38.89) | 29.6817 |
| 2010's | 38 (42.22) | 24.3611 |
| 2020's | 9 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohammed, GF | 1 |
| Charoo, NA | 1 |
| Makino, ET | 4 |
| Jiang, LI | 1 |
| Stephens, TJ | 1 |
| Mikati, M | 1 |
| Mehta, RC | 4 |
| Wang, J | 1 |
| Fabi, S | 1 |
| Robinson, D | 1 |
| Bajaj, S | 1 |
| Geronemus, R | 1 |
| Bell, M | 1 |
| Widgerow, A | 1 |
| Sadick, N | 1 |
| Pannu, S | 1 |
| Abidi, Z | 1 |
| Arruda, S | 1 |
| Ma, Y | 1 |
| Millette, D | 1 |
| Nalluri, R | 1 |
| Yoo, J | 2 |
| Searle, T | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Nautiyal, A | 1 |
| Wairkar, S | 1 |
| Chaowattanapanit, S | 1 |
| Silpa-Archa, N | 1 |
| Kohli, I | 1 |
| Lim, HW | 1 |
| Hamzavi, I | 1 |
| Vanaman Wilson, MJ | 2 |
| Jones, IT | 2 |
| Bolton, J | 2 |
| Larsen, L | 2 |
| Wu, DC | 1 |
| Goldman, MP | 5 |
| Fabi, SG | 3 |
| Wiznia, LE | 1 |
| Cohen, JM | 1 |
| Beasley, JM | 1 |
| Meehan, SA | 1 |
| Latkowski, JM | 1 |
| Sánchez-Martínez, EM | 1 |
| García-Briz, MI | 1 |
| Moneva-Léniz, LM | 1 |
| Gegúndez-Hernández, H | 1 |
| Pose-Lapausa, P | 1 |
| Mateu-Puchades, A | 1 |
| Dreher, F | 1 |
| Draelos, ZD | 4 |
| Gold, MH | 2 |
| Puissegur Lupo, ML | 1 |
| Tan, SK | 1 |
| Rendon, M | 3 |
| Horwitz, S | 3 |
| Alagappan, U | 1 |
| Tay, YK | 1 |
| Lim, SP | 1 |
| Banga, A | 1 |
| Jain, P | 1 |
| Sigler, ML | 3 |
| Sonti, S | 1 |
| Garruto, J | 2 |
| Gotz, V | 2 |
| Herndon, JH | 2 |
| Clark, CM | 1 |
| Silverberg, JI | 1 |
| Alexis, AF | 3 |
| Chaudhary, S | 1 |
| Dayal, S | 1 |
| Thornfeldt, C | 1 |
| Rizer, RL | 1 |
| Trookman, NS | 1 |
| Suvirya, S | 1 |
| Agrawal, A | 1 |
| Parihar, A | 1 |
| Taheri, A | 1 |
| Mohammadi, M | 1 |
| Raab, S | 2 |
| Yatskayer, M | 2 |
| Chen, N | 1 |
| Krol, Y | 1 |
| Oresajo, C | 2 |
| Gonzalez, N | 1 |
| Perez, M | 1 |
| Shokeen, D | 1 |
| Sofen, B | 1 |
| Prado, G | 1 |
| Emer, J | 1 |
| Deri, B | 1 |
| Kanteev, M | 1 |
| Goldfeder, M | 1 |
| Lecina, D | 1 |
| Guallar, V | 1 |
| Adir, N | 1 |
| Fishman, A | 1 |
| Rendon, MI | 2 |
| Barkovic, S | 1 |
| Schlessinger, J | 2 |
| Saxena, S | 1 |
| Mohr, S | 1 |
| Sarkar, R | 1 |
| Parmar, NV | 1 |
| Kapoor, S | 1 |
| Terrell, S | 1 |
| Aires, D | 1 |
| Schweiger, ES | 1 |
| Grimes, PE | 2 |
| Woodhall, KE | 1 |
| Biron, J | 1 |
| Que, SK | 1 |
| Bergstrom, KG | 1 |
| Gil, I | 1 |
| Segura, S | 1 |
| Martínez-Escala, E | 1 |
| Lloreta, J | 1 |
| Puig, S | 1 |
| Vélez, M | 1 |
| Pujol, RM | 1 |
| Herrero-González, JE | 1 |
| Kenkel, J | 1 |
| Werschler, P | 1 |
| Rossi, AM | 1 |
| Perez, MI | 1 |
| Chandra, M | 1 |
| Levitt, J | 1 |
| Pensabene, CA | 1 |
| Bruce, S | 1 |
| Watson, J | 1 |
| Konda, S | 1 |
| Geria, AN | 1 |
| Halder, RM | 1 |
| Kolbe, L | 1 |
| Mann, T | 1 |
| Gerwat, W | 1 |
| Batzer, J | 1 |
| Ahlheit, S | 1 |
| Scherner, C | 1 |
| Wenck, H | 1 |
| Stäb, F | 1 |
| Dahl, A | 1 |
| Kasraee, B | 1 |
| Yoshimura, K | 5 |
| Momosawa, A | 4 |
| Watanabe, A | 1 |
| Sato, K | 3 |
| Matsumoto, D | 3 |
| Aiba, E | 3 |
| Harii, K | 5 |
| Yamamoto, T | 1 |
| Aoyama, T | 4 |
| Iga, T | 4 |
| Mitoma, Y | 1 |
| Briganti, S | 1 |
| Camera, E | 1 |
| Picardo, M | 2 |
| Gupta, AK | 1 |
| Ryder, JE | 1 |
| Uchida, G | 1 |
| Yamaoka, H | 1 |
| Mihara, S | 1 |
| Tsukamoto, K | 1 |
| LANGHOF, H | 1 |
| ZABEL, R | 1 |
| SIDI, E | 1 |
| BOURGEOIS-SPINASSE, J | 1 |
| PLANAT, P | 1 |
| Nanda, S | 1 |
| Grover, C | 1 |
| Reddy, BS | 1 |
| Bellew, SG | 1 |
| Alster, TS | 2 |
| Kooyers, TJ | 1 |
| Westerhof, W | 1 |
| Yoon, TY | 1 |
| Lee, GC | 1 |
| Kim, YG | 1 |
| Kim, MK | 1 |
| Kim, CY | 1 |
| POLLOCK, JH | 1 |
| Cayce, KA | 1 |
| McMichael, AJ | 1 |
| Feldman, SR | 1 |
| Kim, YJ | 1 |
| Lee, HS | 1 |
| Son, SW | 1 |
| Kim, SN | 1 |
| Kye, YC | 1 |
| Bongiorno, MR | 1 |
| Aricò, M | 1 |
| Boissy, RE | 1 |
| Visscher, M | 1 |
| DeLong, MA | 1 |
| Callender, VD | 2 |
| Gathse, A | 1 |
| Ibara, JR | 1 |
| Nordlund, JJ | 1 |
| Ortonne, JP | 1 |
| Lowe, N | 1 |
| Tanghetti, E | 1 |
| Draelos, Z | 1 |
| Menter, A | 1 |
| Taylor, SC | 1 |
| Burgess, CM | 1 |
| Fu, J | 1 |
| Roberts, WE | 1 |
| Shalita, AR | 1 |
| Lynde, CB | 1 |
| Kraft, JN | 1 |
| Lynde, CW | 1 |
| Hexsel, D | 1 |
| Arellano, I | 1 |
| Smiles, KA | 1 |
| Dong, KK | 1 |
| Canning, MT | 1 |
| Grimson, R | 1 |
| Walfield, AM | 1 |
| Yarosh, DB | 1 |
| Carrera, M | 1 |
| Charlín, R | 1 |
| Barcaui, CB | 1 |
| Kac, BK | 1 |
| Soares, DB | 1 |
| Rabello-Fonseca, R | 1 |
| Azulay-Abulafia, L | 1 |
| Kurita, M | 2 |
| Ozaki, M | 1 |
| Miyamoto, S | 1 |
| Kobayashi, Y | 1 |
| Ban, I | 1 |
| Kato, H | 1 |
| Burns, RL | 1 |
| Prevost-Blank, PL | 1 |
| Lawry, MA | 1 |
| Lawry, TB | 1 |
| Faria, DT | 1 |
| Fivenson, DP | 1 |
| Fisher, AA | 1 |
| Amer, M | 1 |
| Metwalli, M | 1 |
| West, TB | 1 |
| Hasan, AT | 1 |
| Eaglstein, W | 1 |
| Pardo, RJ | 1 |
| Gladstone, HB | 1 |
| Nguyen, SL | 1 |
| Williams, R | 1 |
| Ottomeyer, T | 1 |
| Wortzman, M | 1 |
| Jeffers, M | 1 |
| Moy, RL | 1 |
| Ozluer, SM | 1 |
| Muir, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation, A Randomized Double-blind and Vehicle-Controlled Study[NCT03926845] | 200 participants (Actual) | Interventional | 2019-04-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
23 reviews available for hydroquinone and Hypermelanosis
| Article | Year |
|---|---|
Hyperpigmentation: Looking beyond hydroquinone.
Topics: Adult; Humans; Hydroquinones; Hyperpigmentation; Middle Aged; Ochronosis | 2022 |
Hydroquinone: myths and reality.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Drug Therapy, Combination; Humans; Hydroquinones | 2021 |
Management of hyperpigmentation: Current treatments and emerging therapies.
Topics: Glycolates; Humans; Hydroquinones; Hyperpigmentation; Pyrones; Skin | 2021 |
Differential diagnosis and management of hyperpigmentation.
Topics: Diagnosis, Differential; Humans; Hydroquinones; Hyperpigmentation; Melanins; Melanocytes; Skin Cream | 2022 |
Postinflammatory hyperpigmentation: A comprehensive overview: Treatment options and prevention.
Topics: Antioxidants; Chemexfoliation; Dermatitis; Dermatologic Agents; Drug Combinations; Humans; Hydroquin | 2017 |
Topical treatment of hyperpigmentation disorders.
Topics: Administration, Topical; Adrenal Cortex Hormones; Arbutin; Chromones; Drug Combinations; Free Radica | 2012 |
New and emerging treatments for hyperpigmentation.
Topics: Administration, Cutaneous; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hydroquinones; Hype | 2014 |
Natural Cosmeceutical Ingredients for Hyperpigmentation.
Topics: Arbutin; Cosmeceuticals; Glycine max; Humans; Hydroquinones; Hyperpigmentation; Melanocytes; Plant E | 2016 |
Postinflammatory hyperpigmentation in patients with skin of color.
Topics: Chemexfoliation; Dermatitis; Dermatologic Agents; Dicarboxylic Acids; Drug Combinations; Ethanol; Gl | 2016 |
Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.
Topics: Dermatologic Agents; Humans; Hydroquinones; Hyperpigmentation; Inflammation; Melanosis; Phototherapy | 2016 |
Management of hyperpigmentation in darker racial ethnic groups.
Topics: Antioxidants; Chemexfoliation; Dermabrasion; Humans; Hydroquinones; Hyperpigmentation; Laser Therapy | 2009 |
Hydroquinone therapy for post-inflammatory hyperpigmentation secondary to acne: not just prescribable by dermatologists.
Topics: Acne Vulgaris; Bleaching Agents; Humans; Hydroquinones; Hyperpigmentation; Monophenol Monooxygenase | 2012 |
New horizons in treating disorders of hyperpigmentation in skin of color.
Topics: Administration, Oral; Administration, Topical; Chemexfoliation; Dermatologic Agents; Humans; Hydroqu | 2012 |
[Topical treatment of hyperpigmentation disorders].
Topics: Drug Therapy, Combination; Humans; Hydroquinones; Hyperpigmentation; Randomized Controlled Trials as | 2012 |
Chemical and instrumental approaches to treat hyperpigmentation.
Topics: Animals; Humans; Hydroquinones; Hyperpigmentation; Laser Therapy; Melanins; Melanocytes; Monophenol | 2003 |
[Toxicological aspects and health risks associated with hydroquinone in skin bleaching formula].
Topics: Administration, Topical; Cosmetics; Dose-Response Relationship, Drug; Face; Humans; Hydroquinones; H | 2004 |
Hyperpigmentation: an overview of the common afflictions.
Topics: Chemexfoliation; Cryotherapy; Dermatologic Agents; Dicarboxylic Acids; Humans; Hydroquinones; Hyperp | 2004 |
Considerations for treating acne in ethnic skin.
Topics: Acne Keloid; Acne Vulgaris; Black People; Cosmetics; Dicarboxylic Acids; Drug Therapy, Combination; | 2005 |
The safety of hydroquinone.
Topics: Animals; Cosmetics; Humans; Hydroquinones; Hyperpigmentation; Occupational Exposure; Phytotherapy; S | 2006 |
Postinflammatory hyperpigmentation: evolving combination treatment strategies.
Topics: Adolescent; Adult; Antioxidants; Combined Modality Therapy; Dermabrasion; Dermatitis; Dermatologic A | 2006 |
Topical treatments for melasma and postinflammatory hyperpigmentation.
Topics: Administration, Topical; Dermatologic Agents; Female; Humans; Hydroquinones; Hyperpigmentation; Infl | 2006 |
New and experimental treatments of cloasma and other hypermelanoses.
Topics: Chemexfoliation; Dermatologic Agents; Drug Combinations; Flavonoids; Glucocorticoids; Humans; Hydroq | 2007 |
The use of hydroquinone with facial laser resurfacing.
Topics: Erythema; Humans; Hydroquinones; Hyperpigmentation; Laser Therapy; Lasers; Radiation-Protective Agen | 2000 |
27 trials available for hydroquinone and Hypermelanosis
| Article | Year |
|---|---|
Topical Cyperus rotundus essential oil for treatment of axillary hyperpigmentation: a randomized, double-blind, active- and placebo-controlled study.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Axilla; Colorimetry; Cost-Benefit Analysis | 2022 |
A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Topics: Administration, Cutaneous; Dermatologic Agents; Humans; Hydroquinones; Hyperpigmentation; Melanosis; | 2023 |
A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Topics: Administration, Cutaneous; Adult; Aged; Dermatologic Agents; Facial Dermatoses; Female; Humans; Hydr | 2017 |
The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
Topics: Administration, Cutaneous; Adult; Aged; Antioxidants; Face; Female; Humans; Hydroquinones; Hyperpigm | 2018 |
Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Dose-Response Relationship, Radiation; Double | 2013 |
Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Topics: Administration, Cutaneous; Adult; Aged; Dermatologic Agents; Dinoprostone; Dose-Response Relationshi | 2013 |
Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Female; Follow-Up Studies; Humans; Hydroquino | 2013 |
Efficacy of combination of glycolic acid peeling with topical regimen in treatment of melasma.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Chemexfoliation; Female; Glycolates; Humans; Hydrocor | 2013 |
A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone.
Topics: Adolescent; Adult; Aged; Face; Female; Humans; Hydroquinones; Hyperpigmentation; Middle Aged; Peroxi | 2015 |
A method for maintaining the clinical results of 4% hydroquinone and 0.025% tretinoin with a cosmeceutical formulation.
Topics: Adult; Cosmeceuticals; Double-Blind Method; Female; Humans; Hydroquinones; Hyperpigmentation; Kerato | 2015 |
Split-Face Comparison of an Advanced Non-Hydroquinone Lightening Solution to 4% Hydroquinone.
Topics: Double-Blind Method; Drug Compounding; Face; Follow-Up Studies; Humans; Hydroquinones; Hyperpigmenta | 2016 |
Treatment of Postinflammatory Hyperpigmentation With a Combination of Glycolic Acid Peels and a Topical Regimen in Dark-Skinned Patients: A Comparative Study.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Chemexfoliation; Drug Combinations; Faci | 2017 |
Benefits of using a hydroquinone/tretinoin skin care system in patients undergoing intense pulsed light therapy for photorejuvenation: a placebo-controlled study.
Topics: Administration, Cutaneous; Adult; Female; Follow-Up Studies; Humans; Hydroquinones; Hyperpigmentatio | 2009 |
Further enhancement of facial appearance with a hydroquinone skin care system plus tretinoin in patients previously treated with botulinum toxin Type A.
Topics: Administration, Cutaneous; Botulinum Toxins, Type A; Face; Female; Follow-Up Studies; Humans; Hydroq | 2011 |
Evaluation of a prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for normal to oily skin.
Topics: Adult; Ascorbic Acid; Dermatologic Agents; Drug Combinations; Female; Follow-Up Studies; Humans; Hyd | 2011 |
4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation.
Topics: Administration, Topical; Aged; Arbutin; Female; Humans; Hydroquinones; Hyperpigmentation; Melanins; | 2013 |
Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone.
Topics: Adult; Aged; Chemistry, Pharmaceutical; Double-Blind Method; Ellagic Acid; Ethnicity; Face; Female; | 2013 |
Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Topics: Adult; Aged; Antioxidants; Chemistry, Pharmaceutical; Color; Dermatologic Agents; Dinoprostone; Dose | 2012 |
Clinical trial of bleaching treatment with 10% all-trans retinol gel.
Topics: Adult; Aged; Ascorbic Acid; Dermatitis, Irritant; Drug Therapy, Combination; Erythema; Female; Gels; | 2003 |
Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma.
Topics: Administration, Topical; Adolescent; Adult; Chemexfoliation; Double-Blind Method; Female; Humans; Hy | 2004 |
Novel approach to the treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream.
Topics: Administration, Topical; Adult; Dermatologic Agents; Double-Blind Method; Drug Combinations; Emollie | 2005 |
Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study.
Topics: Administration, Topical; Chi-Square Distribution; Dermatologic Agents; Double-Blind Method; Female; | 2006 |
A hydroquinone formulation with increased stability and decreased potential for irritation.
Topics: Adult; Alkaloids; Antioxidants; Cells, Cultured; Dermatitis, Irritant; Dermatologic Agents; Drug Com | 2007 |
Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study.
Topics: Administration, Topical; Adult; Black People; Chemexfoliation; Dermatitis; Drug Combinations; Female | 1997 |
Topical hydroquinone in the treatment of some hyperpigmentary disorders.
Topics: Adolescent; Adult; Dermatologic Agents; Female; Humans; Hydroquinones; Hyperpigmentation; Male; Midd | 1998 |
Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing.
Topics: Administration, Cutaneous; Adult; Carbon Dioxide; Dermatologic Surgical Procedures; Facial Dermatose | 1999 |
Efficacy of hydroquinone cream (USP 4%) used alone or in combination with salicylic acid peels in improving photodamage on the neck and upper chest.
Topics: Chemexfoliation; Female; Glycolates; Humans; Hydroquinones; Hyperpigmentation; Keratolytic Agents; M | 2000 |
40 other studies available for hydroquinone and Hypermelanosis
| Article | Year |
|---|---|
Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum.
Topics: Administration, Cutaneous; Adult; Female; Humans; Hydroquinones; Hyperpigmentation; Melanosis; Pregn | 2022 |
Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation.
Topics: Adult; Female; Humans; Hyperpigmentation; Melanosis; Retinoids; Skin | 2023 |
UK-based dermatologist online survey on the current practice and training in the management of melasma and postinflammatory hyperpigmentation.
Topics: Administration, Topical; Alkaptonuria; Dermatologists; Drug Therapy, Combination; Humans; Hydroquino | 2020 |
Lymphomatoid papulosis.
Topics: Aged; Clobetasol; Glucocorticoids; Humans; Hydroquinones; Hyperpigmentation; Lymphomatoid Papulosis; | 2018 |
Exogenous ochronosis: the failure of depigmenting creams.
Topics: Antioxidants; Back; Facial Dermatoses; Female; Humans; Hydroquinones; Hyperpigmentation; Middle Aged | 2019 |
Efficacy of hydroquinone-free skin-lightening cream for photoaging.
Topics: Administration, Cutaneous; Adult; Aged; California; Dermatologic Agents; Drug Combinations; Female; | 2013 |
Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser.
Topics: Adult; Aged; Asian People; Facial Dermatoses; Female; Humans; Hydroquinones; Hyperpigmentation; Lase | 2013 |
Pigmented contact dermatitis secondary to benzyl salicylate.
Topics: Administration, Cutaneous; Aged; Cosmetics; Dermatitis, Contact; Female; Humans; Hydroquinones; Hype | 2013 |
A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI.
Topics: Cosmetic Techniques; Erbium; Humans; Hydroquinones; Hyperpigmentation; Laser Therapy; Lasers, Solid- | 2013 |
Blockade of melanin synthesis, activation and distribution pathway by a nonprescription natural regimen is equally effective to a multiple prescription-based therapeutic regimen.
Topics: Adult; Biological Products; Dermatologic Agents; Female; Follow-Up Studies; Humans; Hydroquinones; H | 2013 |
5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles.
Topics: Adult; Antimetabolites, Antineoplastic; Antioxidants; Biopsy; Clobetasol; Diagnosis, Differential; D | 2014 |
The Use of Cellulose Nanocrystals for Potential Application in Topical Delivery of Hydroquinone.
Topics: Administration, Topical; Cellulose; Drug Delivery Systems; Female; Humans; Hydroquinones; Hyperpigme | 2015 |
The unravelling of the complex pattern of tyrosinase inhibition.
Topics: Bacillus megaterium; Enzyme Inhibitors; Hydroquinones; Hyperpigmentation; Kinetics; Melanins; Monoph | 2016 |
Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI.
Topics: Administration, Cutaneous; Adult; Aged; Drug Compounding; Drug Therapy, Combination; Female; Humans; | 2016 |
Treatment of acne vulgaris using blue light photodynamic therapy in an African-American patient.
Topics: Acne Vulgaris; Adult; Aminolevulinic Acid; Black or African American; Female; Humans; Hydroquinones; | 2009 |
Hyperpigmentation: old problem, new therapies.
Topics: Chemexfoliation; Dermatologic Agents; Dicarboxylic Acids; Fluocinolone Acetonide; Humans; Hydroquino | 2009 |
Dermoscopic and reflectance confocal microscopic features of exogenous ochronosis.
Topics: Benzophenones; Biopsy, Needle; Cosmetics; Dermoscopy; Facial Dermatoses; Female; Follow-Up Studies; | 2010 |
Treatment of hyperpigmentation.
Topics: Anisoles; Combined Modality Therapy; Dermatologic Agents; Drug Therapy, Combination; Humans; Hydroqu | 2011 |
Fractional laser resurfacing of acne scarring in patients with Fitzpatrick skin types IV-VI.
Topics: Acne Vulgaris; Antioxidants; Cicatrix; Humans; Hydroquinones; Hyperpigmentation; Low-Level Light The | 2011 |
Peroxidase-mediated mechanisms are involved in the melanocytotoxic and melanogenesis-inhibiting effects of chemical agents.
Topics: Animals; Catechols; Humans; Hydroquinones; Hyperpigmentation; Melanins; Melanocytes; Melatonin; Meth | 2002 |
Cosmetic color improvement of the nipple-areola complex by optimal use of tretinoin and hydroquinone.
Topics: Administration, Cutaneous; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration | 2002 |
Lustra, Lustra-AF and Alustra.
Topics: Drug Therapy, Combination; Humans; Hydroquinones; Hyperpigmentation; Melanosis; Tretinoin | 2003 |
Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for acquired dermal melanocytosis.
Topics: Adolescent; Adult; Combined Modality Therapy; Dermatologic Agents; Female; Humans; Hydroquinones; Hy | 2003 |
[Treatment of hyperpigmentation with hydroquinone monobenzylether ointment].
Topics: Humans; Hydroquinones; Hyperpigmentation; Melanins; Ointments; Phenols; Pigmentation | 1959 |
[Treatment of hyperpigmentations by hydroquinone derivatives].
Topics: Humans; Hydroquinones; Hyperpigmentation; Pigmentation Disorders; Quinones | 1961 |
Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser.
Topics: Beryllium; Dermatologic Agents; Face; Female; Humans; Hydroquinones; Hyperpigmentation; Laser Therap | 2004 |
A case of idiopathic eruptive macular pigmentation.
Topics: Adult; Diagnosis, Differential; Dicarboxylic Acids; Facial Dermatoses; Female; Humans; Hydroquinones | 2004 |
Hyperpigmentation improved by treatment with monobenzyl ether of hydroquinone.
Topics: Ether; Ethers; Humans; Hydroquinones; Hyperpigmentation; Pigmentation | 1950 |
Analysis of hyperpigmentation and hypopigmentation after Er:YAG laser skin resurfacing.
Topics: Adult; Cicatrix; Female; Follow-Up Studies; Humans; Hydroquinones; Hyperpigmentation; Hypopigmentati | 2005 |
Exogenous ochronosis and striae atrophicae following the use of bleaching creams.
Topics: Atrophy; Dermatologic Agents; Female; Glucocorticoids; Humans; Hydroquinones; Hyperpigmentation; Mid | 2005 |
DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency.
Topics: Agaricales; Animals; Arbutin; Cell Proliferation; Clinical Trials as Topic; Dose-Response Relationsh | 2005 |
[Reasons for consulting related to skin-bleaching products used by 104 women in Brazzaville].
Topics: Acne Vulgaris; Adolescent; Adrenal Cortex Hormones; Adult; Congo; Cosmetics; Dermatologic Agents; De | 2005 |
Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation.
Topics: Administration, Topical; Drug Therapy, Combination; Facial Dermatoses; Fluocinolone Acetonide; Gluco | 2006 |
Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy.
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Dermoscopy; Female; Humans; Hydroquinones; Hy | 2008 |
Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians.
Topics: Administration, Topical; Adult; Asian People; Dermatologic Agents; Eyelids; Female; Humans; Hydroqui | 2008 |
A therapeutic strategy based on histological assessment of hyperpigmented skin lesions in Asians.
Topics: Administration, Topical; Adolescent; Adult; Asian People; Biopsy; Combined Modality Therapy; Dermato | 2009 |
The safety of bleaching creams containing hydroquinone.
Topics: Administration, Topical; Cosmetics; Drug Hypersensitivity; Female; Humans; Hydroquinones; Hyperpigme | 1998 |
Solar-induced postinflammatory hyperpigmentation after laser hair removal.
Topics: Administration, Topical; Adult; Drug Therapy, Combination; Hair Removal; Humans; Hydroquinones; Hype | 1999 |
Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals.
Topics: Administration, Topical; Adolescent; Adult; Asian People; Female; Gels; Humans; Hydroquinones; Hyper | 2000 |
Nail staining from hydroquinone cream.
Topics: Administration, Topical; Adult; Coloring Agents; Facial Dermatoses; Follow-Up Studies; Humans; Hydro | 2000 |